Studies with a panel of monoclonal antibodies (MAbs) reactive towards the presumptive rabbit liver growth-hormone (GH) receptor show that the rabbit serum GH-binding proteins share seven antigenic determinants (three at the hormone-binding site and four located elsewhere) with the liver cytosolic GH-binding proteins and the putative GH 'receptors' associated with the hepatocyte membrane. The rabbit serum binding proteins have an affinity for GH similar to the membrane GH receptors [for human GH, Ka = 2.45 (± 0.15) x 109 M-1 (mean + S.E.M., n = 8)] and high capacity relative to membrane 'GH receptors'. Analogues of the postulated membrane 'receptor' subtypes 1 and 2 exist in the serum, but not subtype 3, which is also absent from liver cytosol. The serum and cytosolic binding proteins have identical cationdependence properties; hGH binding is Ca2+-dependent, whereas oGH binding is Ca2+-independent.
INTRODUCTION
We have previously reported the use of a panel of MAbs to the presumptive GH receptor in rabbit and rat liver [1, 2] to demonstrate a close antigenic and possible ontogenic relationship between membrane 'receptor' subtypes 1 and 2 and the cytosolic GH-binding proteins that are present in large amounts in the rabbit liver [2, 3] . We also reported antigenic mapping studies with these MAbs, on the basis of which we postulated the existence of three subtypes of rabbit liver GH receptor [2] , one of which (type 3) was not recovered after Triton X-100 solubilization ofliver microsomes (microsomal fractions), although it shared at least one antigenic determinant with the other subtypes [2] .
Ymer and co-workers [4] recently reported the existence of a serum GH-binding protein in the rabbit and in man [5] . In the present paper we compare salient physico-chemical and antigenic features (with respect to our MAb panel) of these serum binding proteins with the cytosolic GH-binding proteins and with presumptive receptor subtypes 1, 2 and 3 in the rabbit liver.
MATERIALS AND METHODS Materials
oGH (S-13 and 1-3), hGH (I-1), oPRL-16, rabbit GH (AFP-684C) and rat PRL (B-3) were gifts from the National Hormone and Pituitary Program (Baltimore, MD, U.S.A.). hGH. for receptor purification was generously provided by the Human Pituitary Advisory Committee of Australia (Woden, A. C. T., Australia). Porcine insulin was from Connaught Laboratories (Toronto, Canada).
Hormones were iodinated by the lactoperoxidase method of Thorell & Johansson [6] , as described previously [7] , and fractionated on a Sephadex G-100 column. Rabbit anti-mouse immunoglobulins were purchased from DAKO immunoglobulins (Glostrup, Denmark). Preparation of receptor and binding-protein-containing fractions
The liver receptor preparations used in the present study were derived from a three-stage purification of the GH receptor [7] . Studies on inhibition of [125I]iodohormone binding reported previously [1, 2] were carried out on crude microsomal (100000 g, 60 min) fractions of rabbit liver. The cytosolic preparations used in the present (and previous) studies [2, 3] were the supernatants from the crude microsomal preparations, filtered through Whatman no. 541 filter paper to remove fat. Immunoprecipitation and inhibition experiments were also carried out with Triton X-100 (1%, v/v)-solubilized extracts of these microsomal membranes (300000 g/90 min supernatants) or with rabbit liver GH receptor partially purified from these extracts by differential affinity chromatography on an hGH affinity column [7] . GH-binding proteins were purified by the same affinity-chromatography procedure from serum, Vol. 237 Abbreviations used: GH, growth hormone (somatotropin); PRL, prolactin; the prefixes h and o refer to the human and sheep hormones respectively; MAb, monoclonal antibody; PEG, poly(ethylene glycol); DMSO, dimethyl sulphoxide; PMSF, phenylmethanesulphonyl fluoride; D1T, dithiothreitol; r.r.a., radioreceptor assay.
after addition of MgCl2 to 10 mm. In this case, no Triton X-100 was added to the serum or purification buffers. Laemmli [8] gels of this material showed major bands at 52000 and 80000 Mr, and the degree of purification was 105-fold. These bands presumably contain additional protein impurities, since this preparation was less than 1 % pure as assessed by specific binding activity. Affinity cross-linking This was performed with either hGH-affinity-purified serum binding protein or hGH-affinity-purified liver GH receptor. Binding protein at approx. 10 fmol/ml was incubated for 12-14 h with 1251-hGH (300000 c.p.m./ml) in 20 mM-Hepes buffer [containing 0.1 % Triton X-100, 10 mM-MgCl2, 0.2% bacitracin, leupeptin and pepstatin (10 ug/ml), 1O mM-benzamidine and 1 mM-PMSF] at 20 'C. Disuccinimidyl suberate (Pierce) was added as a 100-fold concentrate in DMSO, with vortex mixing, to give a final concentration of 0.5 mm. Binding protein was left 15 min at 4 'C to cross-link, then cross-linking was blocked by the addition of Tris to 20 mm, pH 7.4. The solution was centrifuged briefly to clarify, then MAb 263 was added to 1:5000 (v/v) final dilution in the Hepes cross-linking buffer. This was left 8-12 h at 4 'C, then goat anti-mouse second antibody was added to a final dilution of 1:200, followed by a further 3 h incubation at 4 'C. Cross-linked, immunoprecipitated, 1251-labelled complexes were harvested by centrifugation (2000 g, 20 min), then solubilized in Laemmli sample buffer with 10 mM-DTT and subjected to slab-gel electrophoresis by the method of Laemmli [8] . Gels were dried and autoradiographed with intensifying screens (LightningPlus; du Pont).
Serum
Serum was obtained from the arterial blood of mature male and female rabbits. After complete clotting at room temperature and 2 h at 4 'C to allow clot retraction, the blood was centrifuged at 4 'C. Serum and cytosol preparations were stored at -20 'C. The Ca2+ concentration in samples was determined by atomic-absorption spectrophotometry.
Assay methods
The cytosolic GH binding proteins and serum GHbinding proteins are PEG-soluble [2, 4] . In order to perform receptor-binding assays by the standard methods [7] , a precipitating MAb (MAb 1), which does not interfere with hormone binding [1] , was added to the incubation mixtures at a 1:1000 dilution in r.r.a. buffer 17 and 10% of added radioactivity [7] . The binding-protein-hormone complexes were then PEG-precipitable. Our previous work [1] has shown that at least half of the affinity-purified rabbit 'GH receptor' is PEG-soluble, so to render the complexes completely PEG-precipitable, MAb 1 was also incorporated in inhibition assays with the affinity-purified 'receptor'.
Cytosol, serum and affinity purified 'GH receptor' preparations were pre-titrated for 1251-hormone binding in a standard r.r.a. [7] (incorporating MAb 1), before precipitation, inhibition or Scatchard [9] experiments.
MAbs used in all experiments were purified from mouse ascitic fluid by (NH4)2SO4 precipitation, followed by dialysis or gel filtration on Sephacryl S-300. Inhibition of GH binding to cytosolic or serum binding proteins A 100,1 portion of appropriately diluted serum, cytosol or affinity-purified rabbit GH receptor was pre-incubated overnight at 4°C with serial dilutions of the test MAb (100,u). Parallel serial dilutions of an unrelated MAb (anti-Brucella) were used as binding controls. A 100 ,ul portion of MAb 1 at 1: 1000 was added to both test and control tubes. A 100gcl portion of 1251-hGH or 251I-oGH was then added (100000 c.p.m.), together with 100 ,ul of r.r.a. buffer or 100 ,ul of excess unlabelled oGH (1 /tg) in the binding control tubes.
Incubation was continued for 4 h at 22°C, followed by precipitation with PEG. Precipitation of binding-protein-hormone or 'GH receptor'-hormone complexes by MAbs Titration of precipitating MAbs against Triton X-100-solubilized receptor-hormone complexes was performed by the standard double-antibody method as detailed in reference [1] . Titration of precipitating MAbs against cytosolic or serum bindingproteins was performed by using PEG to separate bound and free binding proteins as follows. After affinity labelling the diluted preparations overnight at 4 "C with 1251I-GH, serial dilutions of test and control MAbs were added to the labelled complexes, with and without excess unlabelled hormone. The incubation was continued for 3 h at 4°C and the reaction then stopped by PEG precipitation [1 ml of unlabelled bovine y-globulins (0.2%), 1 ml of PEG 6000 (30%, w/v), before vortex-mixing and centrifugation at 1600 g for 25 min].
Determination of affinity constants
Binding affinities of serum and cytosolic GH-binding proteins were estimated by Scatchard [9] analysis of 125I-hormone binding to pre-titrated serum or cytosol in the presence of increasing concentrations of unlabelled hormone. This was carried out as described previously [1, 2, 7] , but with the incorporation of precipitating MAb 1 into the incubation mixture to enable PEG precipitation of binding-protein-hormone complexes from serum or respectively. Non-specific binding was 23 and 21% for hGH and oGH respectively. hGH-affinity-purified receptor was added to a final concentration of 52 fmol/ml. For (b), specific binding of hGH and oGH was 9 and 8 % of added radioactivity respectively. Non-specific binding was 20 and 16% respectively. Binding protein was at a final concentration of 50 or 200 fmol/ml. For (c), specific binding was 22 and 6% for hGH and oGH respectively. Non-specific binding was 17% and 20% respectively.
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Production and characterization of the anti-(GH receptor)

MAbs
This has been described in detail previously [1, 2] . The MAbs do not cross-react with prolactin or insulin receptors in the rabbit or rat. MAbs 263, 7 and 44 inhibit components of GH binding to rabbit liver microsomes, cytosol and affinity-purified 'GH receptor' (see [1, 2] and the Results section). Independence of epitopes recognized by MAbs MAbs were tested for mutual competition and for competition with GH for binding sites in rabbit liver microsomes. The inhibition assays were performed by the standard method [2, 3] with either 1251-MAb or 125I-GH as ligand. In this way, epitopes recognized by MAbs, 1, 2, 5, 7, 263, 43 and 44 were shown to be different, although in some cases (detailed in [2] ) the MAb-binding regions (as distinct from epitopes) overlap. ding capacity was marginally higher in females [12980+1320fmol/ml of undiluted serum in females (n = 4); cf. 9380+ 1070 fmol/ml in males (n = 4, P < 0.05)]. In comparison, the binding capacity of female liver microsomes is 8000 + 1600 fmol/g of liver homogenized and the affinity for hGH is approx. 3 x 109 M-1 [7, 10] .
RESULTS
Comparative precipitation curves
When serum was centrifuged at 100000 g for 1 h at 4°C, the binding capacity and affinity estimates were not decreased (paired t test; P > 0.10 at all points on displacement curves from which Scatchard plots were derived), so GH-binding sites on blood cells are not interfering in the assay systems. Specificity of the serum-binding-protein binding sites Fig. 4(a) shows the competition of oGH, hGH, oPRL and porcine insulin for 1251-hGH-binding sites precipitable from male serum by MAb 1. As for membrane-associated GH-binding sites, PRL competes with the GHs, but with approx. 10-fold lower potency than oGH (see [7] ). Insulin has no effect on GH binding to the serum binding proteins, even at concentrations as high as 1O ,g/ml. Fig.  4(b) shows the competition of rabbit GH and rat prolactin for 1251-hGH-binding sites precipitable from male rabbit serum. The homologous ligand, rabbit GH, [12] with rabbit liver membrane GH-binding sites).
Competition;by rat prolactin is less than 20% when 10 jug/ml is added. Hughes [11] has shown that rabbit and rat PRL bind with similar low affinity to rabbit liver membranes. In view of the demonstrated similarity between serum-and membrane-associated GH-binding proteins, it is likely that rabbit and rat PRL will have comparably low affinities for the serum GH-binding proteins. If this be so, then the weak competition by rat PRL for GH-binding sites on the serum GH-binding proteins reflects the effective discrimination between homologous somatotrophic and lactogenic ligands by the rabbit serum binding proteins.
Ca2+ -dependence of GH binding to serum, cytosol and microsomes hGH binds to serum (Fig. 5a ) and cytosolic binding proteins ( Fig. 5b) with virtually complete Ca2+-dependence. Physiological concentrations of Na+ can largely obviate the requirement for Ca2 , so that, in the presence of Na+, a smaller Ca2+-potentiated component is observed (Figs. Sa and b) . By contrast, oGH binding to cytosolic or serum binding proteins is not Ca2+-dependent or Ca2+-potentiated (Figs. Sc and a) . This is significant, since the Ca2+-dependent hGH binding is completely displaceable by oGH. Apparently these ligands bind to the same sites, but with different cation-dependencies. hGH binding to liver microsomes is also Ca2+-dependent, and oGH binding is not, in a manner parallel with that for serum and cytosolic binding proteins (results not shown). Affinity labelling Fig. 6 shows the close similarity between serum and liver-membrane-derived GH-binding proteins, in that both run at 55000 Mr (when 22000 is subtracted for the contribution of hGH), and, in both cases, the radioligand is displaceable by 5 ,g of hGH/ml included in the original incubation mixture. Although total displacement was not obtained for the membrane-derived binding protein, residual binding in the presence of excess unlabelled hormone is small relative to the uncompetedfor 77000 Mr complex. The displaceable component at 45000 Mr probably represents hGH dimer. This implies that the hGH dimer is capable of binding to membrane and serum binding proteins, since the cross-linked hGH-receptor complex is immunoprecipitated with anti-receptor antibody before electrophoresis.
DISCUSSION
The ligand-binding studies hitherto performed by numerous workers (for review, see' [13] ) have, with rare exception, not addressed the question of the relevance of the GH-binding sites detected to the mediation of GH actions. Grichting and co-workers [14] did not detect gross differences in binding capacity of adipoctyes sensitive or refractory to the insulin-like actions of GH, but could not rule out modulation of small subsets of receptors. Baxter & Zaltsman [15] showed that Somatomedin-C levels positively correlated with 'GH receptor' number in hypophysectomized rats, but negatively correlated in intact animals. The 20000-Mr variant of hGH is equipotent with 22000-Mr hGH in stimulating growth in hypophysectomized rats [16] , but is a poor inhibitor of 22000-Mr hGH binding to rabbit liver microsomes [17] . Hughes et al. [12] showed that 20000-Mr hGH was bound with high affinity only by a subset of 'receptors' in the rabbit. To understand these results, the equation of subsets of GH-binding sites with metabolic actions is essential.
The existence of a close structural relationship between subsets of membrane-associated GH-binding sites (the putative 'receptor' subtypes 1 and 2 [2] of the liver GH-binding sites [2] , as well as selective ligand binding to the 'receptor' subtypes so defined [2, 3] . Analogues of subtypes 1 and 2 exist in large amounts in liver cytosol [2, 3] . The present work shows the existence in the circulation of corresponding proteins sharing epitopes with membrane 'GH receptor' subtypes 1 and 2 and cytosolic binding proteins. The common epitopes are located both in the hormone-binding region and elsewhere.
The existence of a 'type 3' GH receptor in rabbit liver membranes was inferred from our earlier antigenic mapping studies [2] . Inhibition of specific 1251-oGH binding to rabbit liver membranes was not total, even at high MAb 7 concentrations (although maximum inhibition obtained could be augmented with MAb 263) [2] . MAb 7 could, however, totally inhibit rat 125I-GH binding to rabbit liver membranes [2] . By contrast, MAb 7 totally inhibits '251-oGH binding to serum or cytosol. These results can be interpreted as evidence against the presence of the 'type 3' GH receptor in serum and cytosol, although it is present in liver microsomes before solubilization and in plasma membrane or endoplasmicreticulum fractions derived from the microsomes [2, 3] .
The possibility emerges that the cytosolic GH-binding proteins may be newly synthesized serum binding proteins in transit to the cell membrane and thence the circulation, or even endocytosed serum binding proteins.
We have previously shown that the same antigens are associated with GH-binding sites in both endoplasmicreticulum and plasma-membrane fractions from hepatocytes. It is now apparent that antigenically identical analogues of presumptive receptor subtypes 1 and 2 exist in the endoplasmic reticulum, cytosol, hepatocyte membrane and the circulation. These findings strongly implicate the liver as a site of synthesis of the serum GH-binding proteins.
In their studies of hGH heterogeneity, Stolar et al. [18] and other groups [19] [20] [21] were unable to demonstrate binding of exogenous GH to human plasma proteins, by gel filtration of plasma/GH co-incubation mixtures. However, these studies did not rule out the possibility of non-covalent interaction between hGH and plasma proteins. Our work supports the finding of Ymer et al. [4] that GH is bound with high affinity by a specific binding protein in the rabbit and in man [5] . Furthermore, the application of MAbs has enabled quantification and antigenic characterization of the serum GH-binding protein in the rabbit. In addition, we have shown that the major GH-binding subunit of both liver and serum that is immunoprecipitated by MAb 263 has an Mr of 55000.
The rabbit serum binding protein has high affinity for hGH (2.45 x 109 M-1) and is present in substantial amounts in the serum (-13 pmol/ml of undiluted female serum; cf. 8 pmol of microsomal 'receptor'/g of female liver homogenized). Given the quantity of serum binding protein and the similar affinities of membrane and serum-binding-protein binding sites for GH, the conditions exist for the controlled exchange of GH from serum binding proteins to membrane receptors.
The binding capacity we measure in male or non-pregnant female rabbits is higher than that reported by Ymer et al. [4] [our value 13 pmol/ml (female); cf.
3.8 pfmol/ml [4] ]. Ymer et al. [4] used a gel-filtration system at room temperature to separate bound from free ligand. This process may well involve some dissociation ofbound hormone, as evidenced by the small competition of oPRL for serum binding sites reported by these workers (although Ymer et al. [22] did report substantial displacement of '25I-hGH from the cytosolic binding protein by oPRL when the gel-filtration method was used). We find substantial displacement of 125I-hGH from the serum binding proteins by oPRL, albeit with 20-fold lower potency than hGH, as for membraneassociated 'GH receptors' [7] . This result is consistent with the similarity of the serum binding protein to membrane-associated 'GH receptors' and cytosolic binding proteins in four other respects (i.e. antigenic identity of binding and other sites, similar affinity, differential ligand binding [3] and identical cation-dependence).
Our estimate of the affinity of the serum binding protein for hGH [2. 45 (+0.15) x 109 M-1] is close to values reported for membrane-associated 'GH receptor' [7, 10] and cytosolic binding proteins [2, 22] .
It is significant that the serum binding proteins show the same differential binding of hGH and oGH as do the cytosolic and membrane-associated binding sites [3] . Our finding, that oGH and hGH binding to the same sites is Ca2+-independent in the former case and Ca2+-dependent in the latter case, supports our earlier observations of differential ligand binding [3] . In studies of GH-binding sites in the mouse liver, Ciccia-Torres & Dellacha [23] raised the possibility of shared binding sites that bound lactogenic and somatogenic ligands with different cation-dependencies.
Differential binding of GH variants to the serum binding proteins could control their particular availability to membrane GH receptors in target organs or the rate of clearance ofdifferent GHs from the circulation (Baumann et al. [24] have recently shown that the 20000-and 22000-Mr GHs have different metabolic half-lives). Discrimination of PRL and GH by the serum binding protein may be significant in this regard. Shiu's study with the MCF-7 and T-47D mammary-tumour-cell lines [25] showed that both hGH and hPRL bind with similar affinity to the PRL receptor in these human cells. Kleinberg & Todd [26] have found that hGH is a potent lactogen in subhuman primates. Sequestration ofhGH by the circulating serum binding proteins could be necessary to prevent a permanent state of galactorrhoea. Conversely, a deficiency of serum GH-binding proteins could have a role in the aetiology of galactorrhoea.
The serum GH-binding proteins are likely to play a crucial role in regulating availability of GH to membrane-associated receptors or the cell interior.
